Jlb & Associates Inc Amgen Inc Transaction History

Jlb & Associates Inc

  • $725 Million
  • Q3 2024

A detailed history of Jlb & Associates Inc transactions in Amgen Inc stock. As of the latest transaction made, Jlb & Associates Inc holds 68,939 shares of AMGN stock, worth $19.6 Million. This represents 3.06% of its overall portfolio holdings.

Number of Shares
68,939
Previous 69,387 0.65%
Holding current value
$19.6 Million
Previous $21.7 Million 2.46%
% of portfolio
3.06%
Previous 3.13%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 02, 2024
SELL
$309.38 - $337.38 $138,602 - $151,146
-448 Reduced 0.65%
68,939 $22.2 Million
Q2 2024

Jul 18, 2024
SELL
$262.75 - $319.31 $67,264 - $81,743
-256 Reduced 0.37%
69,387 $21.7 Million
Q1 2024

Apr 30, 2024
SELL
$268.87 - $324.56 $135,241 - $163,253
-503 Reduced 0.72%
69,643 $19.8 Million
Q4 2023

Jan 22, 2024
SELL
$255.7 - $288.46 $8,949 - $10,096
-35 Reduced 0.05%
70,146 $20.2 Million
Q3 2023

Nov 01, 2023
SELL
$218.65 - $271.46 $868,915 - $1.08 Million
-3,974 Reduced 5.36%
70,181 $18.9 Million
Q2 2023

Jul 20, 2023
BUY
$214.27 - $253.37 $12,856 - $15,202
60 Added 0.08%
74,155 $16.5 Million
Q1 2023

Apr 25, 2023
BUY
$225.79 - $275.2 $182,438 - $222,361
808 Added 1.1%
74,095 $17.9 Million
Q4 2022

Jan 26, 2023
SELL
$229.03 - $291.01 $84,283 - $107,091
-368 Reduced 0.5%
73,287 $19.2 Million
Q3 2022

Oct 19, 2022
SELL
$224.46 - $253.15 $22,446 - $25,315
-100 Reduced 0.14%
73,655 $16.6 Million
Q2 2022

Jul 19, 2022
SELL
$230.71 - $256.74 $36,221 - $40,308
-157 Reduced 0.21%
73,755 $17.9 Million
Q1 2022

Apr 08, 2022
BUY
$219.27 - $242.57 $278,692 - $308,306
1,271 Added 1.75%
73,912 $17.9 Million
Q4 2021

Jan 26, 2022
BUY
$198.88 - $227.6 $548,113 - $627,265
2,756 Added 3.94%
72,641 $16.3 Million
Q3 2021

Nov 10, 2021
BUY
$212.27 - $248.7 $410,742 - $481,234
1,935 Added 2.85%
69,885 $14.9 Million
Q2 2021

Jul 29, 2021
BUY
$233.58 - $259.14 $46,015 - $51,050
197 Added 0.29%
67,950 $16.6 Million
Q1 2021

May 13, 2021
SELL
$221.91 - $258.6 $65,019 - $75,769
-293 Reduced 0.43%
67,753 $16.9 Million
Q4 2020

Jan 28, 2021
BUY
$216.38 - $257.67 $48,036 - $57,202
222 Added 0.33%
68,046 $15.6 Million
Q3 2020

Oct 16, 2020
SELL
$234.65 - $260.95 $269,143 - $299,309
-1,147 Reduced 1.66%
67,824 $17.2 Million
Q2 2020

Jul 13, 2020
SELL
$197.81 - $242.74 $249,042 - $305,609
-1,259 Reduced 1.79%
68,971 $16.3 Million
Q1 2020

May 19, 2020
SELL
$182.24 - $241.7 $315,275 - $418,141
-1,730 Reduced 2.4%
70,230 $14.2 Million
Q4 2019

Feb 10, 2020
BUY
$189.21 - $243.2 $350,606 - $450,649
1,853 Added 2.64%
71,960 $17.3 Million
Q3 2019

Oct 29, 2019
BUY
$174.11 - $208.62 $131,801 - $157,925
757 Added 1.09%
70,107 $13.6 Million
Q2 2019

Aug 05, 2019
BUY
$166.7 - $195.41 $236,213 - $276,895
1,417 Added 2.09%
69,350 $12.8 Million
Q1 2019

Apr 30, 2019
BUY
$180.87 - $203.88 $187,923 - $211,831
1,039 Added 1.55%
67,933 $12.9 Million
Q4 2018

Jan 11, 2019
BUY
$178.4 - $208.25 $13,736 - $16,035
77 Added 0.12%
66,894 $13 Million
Q3 2018

Oct 10, 2018
SELL
$185.29 - $208.89 $665,746 - $750,541
-3,593 Reduced 5.1%
66,817 $13.9 Million
Q2 2018

Jul 09, 2018
BUY
$166.05 - $186.51 $1.09 Million - $1.22 Million
6,544 Added 10.25%
70,410 $13 Million
Q1 2018

Apr 23, 2018
BUY
$169.43 - $198.0 $164,855 - $192,654
973 Added 1.55%
63,866 $10.9 Million
Q4 2017

Jan 24, 2018
BUY
$168.79 - $188.59 $694,233 - $775,670
4,113 Added 7.0%
62,893 $10.9 Million
Q3 2017

Oct 12, 2017
BUY
$167.29 - $191.0 $9.83 Million - $11.2 Million
58,780
58,780 $11 Million

Others Institutions Holding AMGN

# of Institutions
3,119
Shares Held
410M
Call Options Held
7.56M
Put Options Held
7.2M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $152B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Jlb & Associates Inc Portfolio

Follow Jlb & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jlb & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jlb & Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email